Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
John Nutt
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Concepts & Ideas
Procedures
Activities & Behaviors
Anatomy
Physiology
Sign-in to see full Profile
Network (preview)
31
Carter, Julie
24
Payami, Haydeh
16
Horak, Fay
13
Hammerstad, John
11
Zabetian, Cyrus
10
Factor, Stewart
10
Samii, Ali
10
Sexton, Gary
9
Montimurro, Jennifer
9
Calne, Donald
8
Bird, Thomas
8
Griffith, Alida
7
Higgins, Donald
7
Goetz, Christopher
7
Kay, Denise
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of John Nutt (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Franzén Erika; Paquette Caroline; Gurfinkel Victor S; Cordo Paul J; Nutt John G; Horak Fay B
Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease.
Experimental neurology 2009;219(2):430-8.
-
2009: Goetz Christopher G; Nutt John G; Stebbins Glenn T; Chmura Teresa A
Teaching program for the Unified Dyskinesia Rating Scale.
Movement disorders : official journal of the Movement Disorder Society 2009;24(9):1296-8.
-
2009: Goetz Christopher G; Stebbins Glenn T; Wolff David; DeLeeuw William; Bronte-Stewart Helen; Elble Rodger; Hallett Mark; Nutt John; Ramig Lorraine; Sanger Terence; Wu Allan D; Kraus Peter H; Blasucci Lucia M; Shamim Ejaz A; Sethi Kapil D; Spielman Jennifer; Kubota Ken; Grove Andrew S; Dishman Eric; Taylor C Barr
Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device.
Movement disorders : official journal of the Movement Disorder Society 2009;24(4):551-6.
-
2009: Gunzler Steven A; Pavel Misha; Koudelka Caroline; Carlson Nichole E; Nutt John G
Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
Clinical neuropharmacology 2009;32(2):97-102.
-
2009: Jacobs Jesse V; Nutt John G; Carlson-Kuhta Patricia; Stephens Marilee; Horak Fay B
Knee trembling during freezing of gait represents multiple anticipatory postural adjustments.
Experimental neurology 2009;215(2):334-41.
-
2008: Goetz Christopher G; Nutt John G; Stebbins Glenn T
The Unified Dyskinesia Rating Scale: presentation and clinimetric profile.
Movement disorders : official journal of the Movement Disorder Society 2008;23(16):2398-403.
-
2008: Nutt John G; Gunzler Steven A; Kirchhoff Trish; Hogarth Penelope; Weaver Jerry L; Krams Michael; Jamerson Brenda; Menniti Frank S; Landen Jaren W
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.
Movement disorders : official journal of the Movement Disorder Society 2008;23(13):1860-6.
-
2008: Kay Denise M; Factor Stewart A; Samii Ali; Higgins Donald S; Griffith Alida; Roberts John W; Leis Berta C; Nutt John G; Montimurro Jennifer S; Keefe Robert G; Atkins April J; Yearout Dora; Zabetian Cyrus P; Payami Haydeh
Genetic association between alpha-synuclein and idiopathic Parkinson's disease.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2008;147B(7):1222-30.
-
2008: Peterson Amie L; Nutt John G
Treatment of Parkinson's disease with trophic factors.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2008;5(2):270-80.
-
2008: Zhang Jing; Sokal Izabela; Peskind Elaine R; Quinn Joseph F; Jankovic Joseph; Kenney Christopher; Chung Kathryn A; Millard Steven P; Nutt John G; Montine Thomas J
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.
American journal of clinical pathology 2008;129(4):526-9.
-
2008: McCulloch Colin C; Kay Denise M; Factor Stewart A; Samii Ali; Nutt John G; Higgins Donald S; Griffith Alida; Roberts John W; Leis Berta C; Montimurro Jennifer S; Zabetian Cyrus P; Payami Haydeh
Exploring gene-environment interactions in Parkinson's disease.
Human genetics 2008;123(3):257-65.
-
2008: Goetz Christopher G; Laska Eugene; Hicking Christine; Damier Philippe; Müller Thomas; Nutt John; Warren Olanow C; Rascol Olivier; Russ Hermann
Placebo influences on dyskinesia in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2008;23(5):700-7.
-
2008: Gunzler Steven A; Koudelka Caroline; Carlson Nichole E; Pavel Misha; Nutt John G
Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
Archives of neurology 2008;65(2):193-8.
-
2008: Hutter Carolyn M; Samii Ali; Factor Stewart A; Nutt John G; Higgins Donald S; Bird Thomas D; Griffith Alida; Roberts John W; Leis Berta C; Montimurro Jennifer S; Kay Denise M; Edwards Karen L; Payami Haydeh; Zabetian Cyrus P
Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2008;15(2):134-9.
-
2008: Holford Nick; Nutt John G
Disease progression, drug action and Parkinson's disease: why time cannot be ignored.
European journal of clinical pharmacology 2008;64(2):207-16.
-
2008: Ross Donald A; Narus Michael S; Nutt John G
Control of medically refractory restless legs syndrome with intrathecal morphine: case report.
Neurosurgery 2008;62(1):E263; discussion E263.
-
2008: Neuwelt Edward; Abbott N Joan; Abrey Lauren; Banks William A; Blakley Brian; Davis Thomas; Engelhardt Britta; Grammas Paula; Nedergaard Maiken; Nutt John; Pardridge William; Rosenberg Gary A; Smith Quentin; Drewes Lester R
Strategies to advance translational research into brain barriers.
Lancet neurology 2008;7(1):84-96.
-
2008: Powers Karen M; Kay Denise M; Factor Stewart A; Zabetian Cyrus P; Higgins Donald S; Samii Ali; Nutt John G; Griffith Alida; Leis Berta; Roberts John W; Martinez Erica D; Montimurro Jennifer S; Checkoway Harvey; Payami Haydeh
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.
Movement disorders : official journal of the Movement Disorder Society 2008;23(1):88-95.
-
2008: Nutt John G
Pharmacokinetics and pharmacodynamics of levodopa.
Movement disorders : official journal of the Movement Disorder Society 2008;23 Suppl 3():S580-4.
-
2007: Gunzler Steven A; Shakil Saate; Carlson Nichole E; Nutt John G; Meshul Charles K
Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice.
Neuroscience letters 2007;428(2-3):64-7.
-
2007: Wright W G; Gurfinkel V S; Nutt J; Horak F B; Cordo P J
Axial hypertonicity in Parkinson's disease: direct measurements of trunk and hip torque.
Experimental neurology 2007;208(1):38-46.
-
2007: Benice Ted S; Lou Jau-Shin; Eaton Ryan; Nutt John
Hand coordination as a quantitative measure of motor abnormality and therapeutic response in Parkinson's disease.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2007;118(8):1776-84.
-
2007: Zabetian Cyrus P; Hutter Carolyn M; Factor Stewart A; Nutt John G; Higgins Donald S; Griffith Alida; Roberts John W; Leis Berta C; Kay Denise M; Yearout Dora; Montimurro Jennifer S; Edwards Karen L; Samii Ali; Payami Haydeh
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease.
Annals of neurology 2007;62(2):137-44.
-
2007: Chan Phylinda L S; Nutt John G; Holford Nicholas H G
Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.
Pharmaceutical research 2007;24(4):791-802.
-
2007: Nutt John G; Carter Julie H; Carlson Nichole E
Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Archives of neurology 2007;64(3):319-23.
-
2007: Kay Denise M; Moran Dawn; Moses Lina; Poorkaj Parvoneh; Zabetian Cyrus P; Nutt John; Factor Stewart A; Yu Chang-En; Montimurro Jennifer S; Keefe Robert G; Schellenberg Gerard D; Payami Haydeh
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.
Annals of neurology 2007;61(1):47-54.
-
2007: Gunzler Steven A; Stoessl A Jon; Egan Robert A; Weleber Richard G; Wang Paul; Nutt John G
Joubert syndrome surviving to adulthood associated with a progressive movement disorder.
Movement disorders : official journal of the Movement Disorder Society 2007;22(2):262-5.
-
2007: Nutt John G
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Movement disorders : official journal of the Movement Disorder Society 2007;22(1):1-9.
-
2007: Thompson P D; Nutt J G
Higher level gait disorders.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(10):1305-7.
-
2006: Elbaz Alexis; Nelson Lorene M; Payami Haydeh; Ioannidis John P A; Fiske Brian K; Annesi Grazia; Carmine Belin Andrea; Factor Stewart A; Ferrarese Carlo; Hadjigeorgiou Georgios M; Higgins Donald S; Kawakami Hideshi; Krüger Rejko; Marder Karen S; Mayeux Richard P; Mellick George D; Nutt John G; Ritz Beate; Samii Ali; Tanner Caroline M; Van Broeckhoven Christine; Van Den Eeden Stephen K; Wirdefeldt Karin; Zabetian Cyrus P; Dehem Marie; Montimurro Jennifer S; Southwick Audrey; Myers Richard M; Trikalinos Thomas A
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study.
Lancet neurology 2006;5(11):917-23.
-
2006: Gurfinkel Victor; Cacciatore Timothy W; Cordo Paul; Horak Fay; Nutt John; Skoss Rachel
Postural muscle tone in the body axis of healthy humans.
Journal of neurophysiology 2006;96(5):2678-87.
-
2006: Jacobs Jesse V; Horak Fay B; Van Tran K; Nutt John G
An alternative clinical postural stability test for patients with Parkinson's disease.
Journal of neurology 2006;253(11):1404-13.
-
2006: Zabetian Cyrus P; Hutter Carolyn M; Yearout Dora; Lopez Alexis N; Factor Stewart A; Griffith Alida; Leis Berta C; Bird Thomas D; Nutt John G; Higgins Donald S; Roberts John W; Kay Denise M; Edwards Karen L; Samii Ali; Payami Haydeh
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.
American journal of human genetics 2006;79(4):752-8.
-
2006: Brodsky Matthew A; Hogarth Penelope; Nutt John G
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(9):1487-90.
-
2006: Abdi Fadi; Quinn Joseph F; Jankovic Joseph; McIntosh Martin; Leverenz James B; Peskind Elaine; Nixon Randy; Nutt John; Chung Katherine; Zabetian Cyrus; Samii Ali; Lin Melanie; Hattan Stephen; Pan Catherine; Wang Yan; Jin Jinghua; Zhu David; Li G Jane; Liu Yan; Waichunas Dana; Montine Thomas J; Zhang Jing
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.
Journal of Alzheimer's disease : JAD 2006;9(3):293-348.
-
2006: Holford Nicholas H G; Chan Phylinda L S; Nutt John G; Kieburtz Karl; Shoulson Ira;
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Journal of pharmacokinetics and pharmacodynamics 2006;33(3):281-311.
-
2006: Nutt John G
Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Neurology 2006;66(10):1611-2; author reply 1611-2.
-
2006: Kay Denise M; Zabetian Cyrus P; Factor Stewart A; Nutt John G; Samii Ali; Griffith Alida; Bird Tom D; Kramer Patricia; Higgins Donald S; Payami Haydeh
Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.
Movement disorders : official journal of the Movement Disorder Society 2006;21(4):519-23.
-
2006: Lang Anthony E; Langston J William; Stoessl A Jon; Brodsky Matthew; Brooks David J; Dhawan Vijay; Elias William J; Lozano Andres M; Moro Elena; Nutt John G; Stacy Mark; Turner Dennis; Wooten G Frederick
GDNF in treatment of Parkinson's disease: response to editorial.
Lancet neurology 2006;5(3):200-2.
-
2006: Jacobs J V; Horak F B; Tran V K; Nutt J G
Multiple balance tests improve the assessment of postural stability in subjects with Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 2006;77(3):322-6.
-
2006: Lang Anthony E; Gill Steven; Patel Nik K; Lozano Andres; Nutt John G; Penn Richard; Brooks David J; Hotton Gary; Moro Elena; Heywood Peter; Brodsky Matthew A; Burchiel Kim; Kelly Patrick; Dalvi Arif; Scott Burton; Stacy Mark; Turner Dennis; Wooten V G Frederich; Elias William J; Laws Edward R; Dhawan Vijay; Stoessl A Jon; Matcham James; Coffey Robert J; Traub Michael
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
Annals of neurology 2006;59(3):459-66.
-
2006: Blindauer Karen; Shoulson Ira; Oakes David; Kieburtz Karl; Schwid Steven; Fahn Stanley; Stern Matthew; Goetz Christopher; Nutt John; Goren Sari; Sayag Naim; Scolnik Marisa; Levy Ruth; Eyal Eli; Salzman Phyllis; Pagano Mary;
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
Archives of neurology 2006;63(2):210-6.
-
2006: Kay Denise M; Bird Tom D; Zabetian Cyrus P; Factor Stewart A; Samii Ali; Higgins Donald S; Nutt John; Roberts John W; Griffith Alida; Leis Berta C; Montimurro Jennifer S; Philpott Sean; Payami Haydeh
Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease.
Genetic testing 2006;10(3):221-7.
-
2005: Nutt John G; Wooten G Frederick
Clinical practice. Diagnosis and initial management of Parkinson's disease.
The New England journal of medicine 2005;353(10):1021-7.
-
2005: Jacobs Jesse V; Dimitrova Diana M; Nutt John G; Horak Fay B
Can stooped posture explain multidirectional postural instability in patients with Parkinson's disease?
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 2005;166(1):78-88.
-
2005: Chan Phylinda L S; Nutt John G; Holford Nicholas H G
Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.
Journal of pharmacokinetics and pharmacodynamics 2005;32(3-4):459-84.
-
2005: Chan Phylinda L S; Nutt John G; Holford Nicholas H G
Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
Journal of pharmacokinetics and pharmacodynamics 2005;32(3-4):307-31.
-
2005: Horak Fay B; Dimitrova Diana; Nutt John G
Direction-specific postural instability in subjects with Parkinson's disease.
Experimental neurology 2005;193(2):504-21.
-
2005: Chung Kathryn A; Carlson Nichole E; Nutt John G
Short-term paroxetine treatment does not alter the motor response to levodopa in PD.
Neurology 2005;64(10):1797-8.
-
2005: Kachergus Jennifer; Mata Ignacio F; Hulihan Mary; Taylor Julie P; Lincoln Sarah; Aasly Jan; Gibson J Mark; Ross Owen A; Lynch Timothy; Wiley Joseph; Payami Haydeh; Nutt John; Maraganore Demetrius M; Czyzewski Krzysztof; Styczynska Maria; Wszolek Zbigniew K; Farrer Matthew J; Toft Mathias
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.
American journal of human genetics 2005;76(4):672-80.
-
2005: Poorkaj Parvoneh; Moses Lina; Montimurro Jennifer S; Nutt John G; Schellenberg Gerard D; Payami Haydeh
Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism.
BMC neurology 2005;5(1):4.
-
2004: Poorkaj P; Nutt J G; James D; Gancher S; Bird T D; Steinbart E; Schellenberg G D; Payami Haydeh
parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease.
American journal of medical genetics. Part A 2004;129A(1):44-50.
-
2004: Chan Phylinda L S; Nutt John G; Holford Nicholas H G
Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.
Journal of pharmacokinetics and pharmacodynamics 2004;31(3):243-68.
-
2004: Furtado Sarah; Payami Haydeh; Lockhart Paul J; Hanson Melissa; Nutt John G; Singleton Andrew A; Singleton Amanda; Bower Jamel; Utti Ryan J; Bird Thomas D; de la Fuente-Fernandez Raul; Tsuboi Yoshio; Klimek Mary L; Suchowersky Oksana; Hardy John; Calne Donald B; Wszolek Zbigniew K; Farrer Matthew; Gwinn-Hardy Katrina; Stoessl A Jon
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2).
Movement disorders : official journal of the Movement Disorder Society 2004;19(6):622-9.
-
2004: Nutt John G; Carter Julie H; Sexton Gary J
The dopamine transporter: importance in Parkinson's disease.
Annals of neurology 2004;55(6):766-73.
-
2004: Samii Ali; Nutt John G; Ransom Bruce R
Parkinson's disease.
Lancet 2004;363(9423):1783-93.
-
2004: Shults Clifford W; Haas Richard; Oakes David; Kieburtz Karl; Plumb Sandra; Shoulson Ira; Beal M Flint; Juncos Jorge; Nutt John
Measuring the effects of therapy in Parkinson disease.
JAMA : the journal of the American Medical Association 2004;291(20):2430-1; author reply 2431.
-
2004: Dimitrova Diana; Nutt John; Horak Fay B
Abnormal force patterns for multidirectional postural responses in patients with Parkinson's disease.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 2004;156(2):183-95.
-
2004: Olanow C Warren; Damier Philippe; Goetz Christopher G; Mueller Thomas; Nutt John; Rascol Olivier; Serbanescu Alexandru; Deckers Frieda; Russ Hermann
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).
Clinical neuropharmacology 2004;27(2):58-62.
-
2004: Dimitrova Diana; Horak Fay B; Nutt John G
Postural muscle responses to multidirectional translations in patients with Parkinson's disease.
Journal of neurophysiology 2004;91(1):489-501.
-
2003: Nutt John G
Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease.
Experimental neurology 2003;184(1):9-13.
-
2003: Lou Jau-Shin; Kearns Greg; Benice Theodore; Oken Barry; Sexton Gary; Nutt John
Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
Movement disorders : official journal of the Movement Disorder Society 2003;18(10):1108-14.
-
2003: Lou Jau-Shin; Benice Theodore; Kearns Greg; Sexton Gary; Nutt John
Levodopa normalizes exercise related cortico-motoneuron excitability abnormalities in Parkinson's disease.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2003;114(5):930-7.
-
2003: Payami Haydeh; Nutt John; Gancher Steven; Bird Thomas; McNeal Melissa Gonzales; Seltzer William K; Hussey Jennifer; Lockhart Paul; Gwinn-Hardy Katrina; Singleton Amanda A; Singleton Andrew B; Hardy John; Farrer Matthew
SCA2 may present as levodopa-responsive parkinsonism.
Movement disorders : official journal of the Movement Disorder Society 2003;18(4):425-9.
-
2003: Nutt J G; Burchiel K J; Comella C L; Jankovic J; Lang A E; Laws E R; Lozano A M; Penn R D; Simpson R K; Stacy M; Wooten G F;
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
Neurology 2003;60(1):69-73.
-
2002: Shults Clifford W; Oakes David; Kieburtz Karl; Beal M Flint; Haas Richard; Plumb Sandy; Juncos Jorge L; Nutt John; Shoulson Ira; Carter Julie; Kompoliti Katie; Perlmutter Joel S; Reich Stephen; Stern Matthew; Watts Ray L; Kurlan Roger; Molho Eric; Harrison Madaline; Lew Mark;
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Archives of neurology 2002;59(10):1541-50.
-
2002: Nutt John G; Carter Julie H; Lea Eric S; Sexton Gary J
Evolution of the response to levodopa during the first 4 years of therapy.
Annals of neurology 2002;51(6):686-93.
-
2002: Payami Haydeh; Zareparsi Sepideh; James Dora; Nutt John
Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease.
Archives of neurology 2002;59(5):848-50.
-
2002: Gold Bruce G; Nutt John G
Neuroimmunophilin ligands in the treatment of Parkinson's disease.
Current opinion in pharmacology 2002;2(1):82-6.
-
2002: Zareparsi Sepideh; Camicioli Richard; Sexton Gary; Bird Thomas; Swanson Phillip; Kaye Jeffrey; Nutt John; Payami Haydeh
Age at onset of Parkinson disease and apolipoprotein E genotypes.
American journal of medical genetics 2002;107(2):156-61.
-
2001: Nutt J G; Rufener S L; Carter J H; Anderson V C; Pahwa R; Hammerstad J P; Burchiel K J
Interactions between deep brain stimulation and levodopa in Parkinson's disease.
Neurology 2001;57(10):1835-42.
-
2001: Nutt J G
Motor fluctuations and dyskinesia in Parkinson's disease.
Parkinsonism & related disorders 2001;8(2):101-8.
-
2001: Hammerstad J; Burchiel K; Anderson V; Nutt J
Failure of long-term pallidal stimulation corrected by subthalamic stimulation in PD.
Neurology 2001;57(3):566-7.
-
2001: Camicioli R; Lea E; Nutt J G; Sexton G; Oken B S
Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study.
Clinical neuropharmacology 2001;24(4):208-13.
-
2001: Nutt J G; Nygaard T G
Response to levodopa treatment in dopa-responsive dystonia.
Archives of neurology 2001;58(6):905-10.
-
2001: Heikkinen H; Nutt J G; LeWitt P A; Koller W C; Gordin A
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Clinical neuropharmacology 2001;24(3):150-7.
-
2001: Nutt J G; Anderson V C; Peacock J H; Hammerstad J P; Burchiel K J
DBS and diathermy interaction induces severe CNS damage.
Neurology 2001;56(10):1384-6.
-
2001: Payami H; Lee N; Zareparsi S; Gonzales McNeal M; Camicioli R; Bird T D; Sexton G; Gancher S; Kaye J; Calhoun D; Swanson P D; Nutt J
Parkinson's disease, CYP2D6 polymorphism, and age.
Neurology 2001;56(10):1363-70.
-
2001: Lou J S; Kearns G; Oken B; Sexton G; Nutt J
Exacerbated physical fatigue and mental fatigue in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2001;16(2):190-6.
-
2001: Rascol O; Nutt J G; Blin O; Goetz C G; Trugman J M; Soubrouillard C; Carter J H; Currie L J; Fabre N; Thalamas C; Giardina W W; Wright S
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
Archives of neurology 2001;58(2):249-54.
-
2001: Nutt J G
Fluctuations in response to treatment for Parkinson's disease.
Advances in neurology 2001;86():361-6.
-
2001: Nutt J G
Classification of gait and balance disorders.
Advances in neurology 2001;87():135-41.
-
2001: Jankovic J; Nutt J G; Sudarsky L
Classification, diagnosis, and etiology of gait disorders.
Advances in neurology 2001;87():119-33.
-
2000: Frank J S; Horak F B; Nutt J
Centrally initiated postural adjustments in parkinsonian patients on and off levodopa.
Journal of neurophysiology 2000;84(5):2440-8.
-
2000: Nutt J G; Obeso J A; Stocchi F
Continuous dopamine-receptor stimulation in advanced Parkinson's disease.
Trends in neurosciences 2000;23(10 Suppl):S109-15.
-
2000: Obeso J A; Olanow C W; Nutt J G
Levodopa motor complications in Parkinson's disease.
Trends in neurosciences 2000;23(10 Suppl):S2-7.
-
2000: Nutt J G; Lea E S; Van Houten L; Schuff R A; Sexton G J
Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice.
Movement disorders : official journal of the Movement Disorder Society 2000;15(5):843-9.
-
2000: Richard I H; Nutt J
Worsening of motor function in Parkinson's disease: a "typical" response to "atypical" antipsychotic medications.
Neurology 2000;55(6):748-9.
-
2000: Nutt J G
Response to L-dopa in PD: the long and the short of it.
Neurology 2000;54(10):1884-5.
-
2000: Nutt J G
Clinical pharmacology of levodopa-induced dyskinesia.
Annals of neurology 2000;47(4 Suppl 1):S160-4; discussion S164-6.
-
2000: Nutt J G; Carter J H
Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
Neurology 2000;54(1):247-50.
-
2000: Nutt J G
Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Neurology 2000;55(11 Suppl 4):S33-7; discussion S38-41.
-
1999: Zareparsi S; Wirdefeldt K; Burgess C E; Nutt J; Kramer P; Schalling M; Payami H
Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's disease.
Neuroscience letters 1999;272(2):140-2.
-
1999: Jen J; Yue Q; Nelson S F; Yu H; Litt M; Nutt J; Baloh R W
A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia.
Neurology 1999;53(1):34-7.
-
1999: Rascol O; Blin O; Thalamas C; Descombes S; Soubrouillard C; Azulay P; Fabre N; Viallet F; Lafnitzegger K; Wright S; Carter J H; Nutt J G
ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease.
Annals of neurology 1999;45(6):736-41.
-
1999: Nutt J
A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
Movement disorders : official journal of the Movement Disorder Society 1999;14 Suppl 1():74.
-
1999: Melamed E; Olanow C W; Nutt J G; Lang A E
Dyskinesias assessment workshop: reports from the working groups.
Movement disorders : official journal of the Movement Disorder Society 1999;14 Suppl 1():69-73.
-
1998: Carter J H; Nutt J G
Family caregiving: a neglected and hidden part of health care delivery.
Neurology 1998;51(5):1245-6.
-
1998: Thulin P C; Woodward W R; Carter J H; Nutt J G
Levodopa in human breast milk: clinical implications.
Neurology 1998;50(6):1920-1.
-
1998: Maricle R A; Valentine R J; Carter J; Nutt J G
Mood response to levodopa infusion in early Parkinson's disease.
Neurology 1998;50(6):1890-2.
-
1998: Nutt J G
Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
Lancet 1998;351(9111):1221-2.
-
1998: Nutt J G
New pharmacological and surgical therapies for Parkinson's disease.
The Western journal of medicine 1998;168(4):267-8.
-
1998: Zareparsi S; Kaye J; Camicioli R; Kramer P; Nutt J; Bird T; Litt M; Payami H;
Analysis of the alpha-synuclein G209A mutation in familial Parkinson's disease.
Lancet 1998;351(9095):37-8.
-
1998: Camicioli R; Oken B S; Sexton G; Kaye J A; Nutt J G
Verbal fluency task affects gait in Parkinson's disease with motor freezing.
Journal of geriatric psychiatry and neurology 1998;11(4):181-5.
-
1998: Nutt J G
Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.
Advances in pharmacology (San Diego, Calif.) 1998;42():331-4.
-
1997: Zareparsi S; Kaye J; Camicioli R; Grimslid H; Oken B; Litt M; Nutt J; Bird T; Schellenberg G; Payami H
Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes.
Annals of neurology 1997;42(4):655-8.
-
1997: Nutt J G; Carter J H; Van Houten L; Woodward W R
Short- and long-duration responses to levodopa during the first year of levodopa therapy.
Annals of neurology 1997;42(3):349-55.
-
1997: Nutt J G; Gancher S T
A 10-year follow-up--genotypic analysis disproves phenotypic classification.
Movement disorders : official journal of the Movement Disorder Society 1997;12(3):472.
-
1997: Nutt J G; Carter J H; Lea E S; Woodward W R
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1997;12(3):285-92.
-
1997: Burleigh-Jacobs A; Horak F B; Nutt J G; Obeso J A
Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers.
Movement disorders : official journal of the Movement Disorder Society 1997;12(2):206-15.
-
1996: Horak F B; Frank J; Nutt J
Effects of dopamine on postural control in parkinsonian subjects: scaling, set, and tone.
Journal of neurophysiology 1996;75(6):2380-96.
-
1996: Nutt J G; Holford N H
The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
Annals of neurology 1996;39(5):561-73.
-
1996: Gancher S T; Woodward W R; Nutt J G
Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Clinical neuropharmacology 1996;19(1):59-64.
-
1996: Nutt J G
Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA.
Advances in neurology 1996;69():493-6.
-
1995: Burleigh A; Horak F; Nutt J; Frank J
Levodopa reduces muscle tone and lower extremity tremor in Parkinson's disease.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1995;22(4):280-5.
-
1995: Nutt J G
Pharmacodynamics of levodopa in Parkinson's disease.
Clinical and experimental pharmacology & physiology 1995;22(11):837-40.
-
1995: Browne D L; Brunt E R; Griggs R C; Nutt J G; Gancher S T; Smith E A; Litt M
Identification of two new KCNA1 mutations in episodic ataxia/myokymia families.
Human molecular genetics 1995;4(9):1671-2.
-
1995: Carero-Valenzuela R; Lindblad K; Payami H; Johnson W; Schalling M; Stenroos E S; Shattuc S; Nutt J; Brice A; Litt M
No evidence for association of familial Parkinson's disease with CAG repeat expansion.
Neurology 1995;45(9):1760-3.
-
1995: Maricle R A; Nutt J G; Valentine R J; Carter J H
Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.
Neurology 1995;45(9):1757-60.
-
1995: Nutt J G; Carter J H; Woodward W R
Long-duration response to levodopa.
Neurology 1995;45(8):1613-6.
-
1995: Nutt J G
Management of parkinsonism and treatment of associated complications.
Current opinion in neurology 1995;8(4):327-30.
-
1995: Kramer P L; Yue Q; Gancher S T; Nutt J G; Baloh R; Smith E; Browne D; Bussey K; Lovrien E; Nelson S
A locus for the nystagmus-associated form of episodic ataxia maps to an 11-cM region on chromosome 19p.
American journal of human genetics 1995;57(1):182-5.
-
1995: Maricle R A; Nutt J G; Carter J H
Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.
Movement disorders : official journal of the Movement Disorder Society 1995;10(3):329-32.
-
1995: Griggs R C; Nutt J G
Episodic ataxias as channelopathies.
Annals of neurology 1995;37(3):285-7.
-
1995: Gancher S T; Nutt J G; Woodward W R
Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance.
Movement disorders : official journal of the Movement Disorder Society 1995;10(1):37-43.
-
1995: Payami H; Bernard S; Larsen K; Kaye J; Nutt J
Genetic anticipation in Parkinson's disease.
Neurology 1995;45(1):135-8.
-
1994: Hammerstad J P; Woodward W R; Nutt J G; Gancher S T; Block G A; Cyhan G
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
Clinical neuropharmacology 1994;17(5):429-34.
-
1994: Litt M; Kramer P; Browne D; Gancher S; Brunt E R; Root D; Phromchotikul T; Dubay C J; Nutt J
A gene for episodic ataxia/myokymia maps to chromosome 12p13.
American journal of human genetics 1994;55(4):702-9.
-
1994: Browne D L; Gancher S T; Nutt J G; Brunt E R; Smith E A; Kramer P; Litt M
Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1.
Nature genetics 1994;8(2):136-40.
-
1994: Payami H; Larsen K; Bernard S; Nutt J
Increased risk of Parkinson's disease in parents and siblings of patients.
Annals of neurology 1994;36(4):659-61.
-
1994: Nutt J G; Carter J H; Woodward W R
Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects.
Neurology 1994;44(9):1617-22.
-
1994: Nutt J G
Levodopa: rational and irrational pharmacology.
Annals of neurology 1994;36(1):4-5.
-
1994: Nutt J G; Gancher S T
Parkinson's disease dyskinesias.
Neurology 1994;44(6):1187; author reply 1187-8.
-
1994: Nutt J G; Woodward W R; Beckner R M; Stone C K; Berggren K; Carter J H; Gancher S T; Hammerstad J P; Gordin A
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Neurology 1994;44(5):913-9.
-
1993: Burleigh A L; Horak F B; Burchiel K J; Nutt J G
Effects of thalamic stimulation on tremor, balance, and step initiation: a single subject study.
Movement disorders : official journal of the Movement Disorder Society 1993;8(4):519-24.
-
1993: Woodward W R; Olanow C W; Beckner R M; Hauser R A; Gauger L L; Cedarbaum J M; Nutt J G
The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.
Neurology 1993;43(9):1704-8.
-
1993: Butterfield P G; Valanis B G; Spencer P S; Lindeman C A; Nutt J G
Environmental antecedents of young-onset Parkinson's disease.
Neurology 1993;43(6):1150-8.
-
1993: Nutt J G; Carter J H; Woodward W; Hammerstad J P; Gancher S T
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
Movement disorders : official journal of the Movement Disorder Society 1993;8(2):139-43.
-
1993: Nutt J G; Marsden C D; Thompson P D
Human walking and higher-level gait disorders, particularly in the elderly.
Neurology 1993;43(2):268-79.
-
1992: Nutt J G; Woodward W R; Carter J H; Gancher S T
Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.
Archives of neurology 1992;49(11):1123-30.
-
1992: Gancher S T; Nutt J G; Woodward W R
Time course of tolerance to apomorphine in parkinsonism.
Clinical pharmacology and therapeutics 1992;52(5):504-10.
-
1992: Irwin R P; Nutt J G; Woodward W R; Gancher S T
Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.
Clinical neuropharmacology 1992;15(5):365-74.
-
1992: Carter J H; Nutt J G; Woodward W R
The effect of exercise on levodopa absorption.
Neurology 1992;42(10):2042-5.
-
1992: Playford E D; Jenkins I H; Passingham R E; Nutt J; Frackowiak R S; Brooks D J
Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study.
Annals of neurology 1992;32(2):151-61.
-
1992: Horak F B; Nutt J G; Nashner L M
Postural inflexibility in parkinsonian subjects.
Journal of the neurological sciences 1992;111(1):46-58.
-
1992: Grandas F; Gancher S; Lera G; Rodriguez M; Woodward W R; Nutt J; Obeso J A
Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease.
Neurology 1992;42(7):1287-90.
-
1992: Grandas F; Gancher S T; Rodriguez M; Lera G; Nutt J G; Obeso J A
Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
Clinical neuropharmacology 1992;15(1):13-8.
-
1991: Gancher S T; Nutt J G; Woodward W R
Absorption of apomorphine by various routes in parkinsonism.
Movement disorders : official journal of the Movement Disorder Society 1991;6(3):212-6.
-
1990: Lammertsma A A; Cunningham V J; Deiber M P; Heather J D; Bloomfield P M; Nutt J; Frackowiak R S; Jones T
Combination of dynamic and integral methods for generating reproducible functional CBF images.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1990;10(5):675-86.
-
1990: Gancher S T; Woodward W R; Gliessman P; Boucher B; Nutt J G
The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
Annals of neurology 1990;27(6):660-5.
-
1990: Hammerstad J P; Woodward W R; Gliessman P; Boucher B; Nutt J G
L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys.
Annals of neurology 1990;27(5):495-9.
-
1990: Nutt J G
Levodopa-induced dyskinesia: review, observations, and speculations.
Neurology 1990;40(2):340-5.
-
1990: Nilaver G; Whiting S; Nutt J G
Autoimmune etiology for cranial dystonia.
Movement disorders : official journal of the Movement Disorder Society 1990;5(2):179-80.
-
1989: Friston K J; Passingham R E; Nutt J G; Heather J D; Sawle G V; Frackowiak R S
Localisation in PET images: direct fitting of the intercommissural (AC-PC) line.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1989;9(5):690-5.
-
1989: Gancher S T; Woodward W R; Boucher B; Nutt J G
Peripheral pharmacokinetics of apomorphine in humans.
Annals of neurology 1989;26(2):232-8.
-
1989: Nutt J G; Gancher S T; Woodward W R
Motor fluctuations in Parkinson's disease.
Annals of neurology 1989;25(6):633-4.
-
1989: Nutt J G; Woodward W R; Carter J H; Trotman T L
Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa.
Journal of neurology, neurosurgery, and psychiatry 1989;52(4):481-7.
-
1989: Carter J H; Nutt J G; Woodward W R; Hatcher L F; Trotman T L
Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease.
Neurology 1989;39(4):552-6.
-
1988: Nutt J G; Gancher S T; Woodward W R
Does an inhibitory action of levodopa contribute to motor fluctuations?
Neurology 1988;38(10):1553-7.
-
1988: Williams A C; Nutt J G; Hare T
Autoimmunity in stiff man syndrome.
Lancet 1988;2(8604):222.
-
1988: Kurlan R; Nutt J G; Woodward W R; Rothfield K; Lichter D; Miller C; Carter J H; Shoulson I
Duodenal and gastric delivery of levodopa in parkinsonism.
Annals of neurology 1988;23(6):589-95.
-
1988: Gancher S T; Nutt J G; Woodward W
Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations.
Neurology 1988;38(5):712-6.
-
1988: Kurlan R; Rothfield K P; Woodward W R; Nutt J G; Miller C; Lichter D; Shoulson I
Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility.
Neurology 1988;38(3):419-21.
-
1988: Nutt J G; Muenter M D; Melton L J; Aronson A; Kurland L T
Epidemiology of dystonia in Rochester, Minnesota.
Advances in neurology 1988;50():361-5.
-
1988: Jankovic J; Nutt J G
Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence.
Advances in neurology 1988;49():117-23.
-
1988: Nutt J G; Muenter M D; Aronson A; Kurland L T; Melton L J
Epidemiology of focal and generalized dystonia in Rochester, Minnesota.
Movement disorders : official journal of the Movement Disorder Society 1988;3(3):188-94.
-
1988: Nutt J G
The case for and concerns about continuous dopamine stimulation in Parkinson's disease.
Journal of neural transmission. Supplementum 1988;27():11-5.
-
1988: Nutt J G
Parkinsonism: candidate disorder for implanted pumps?
Annals of the New York Academy of Sciences 1988;531():194-9.
-
1987: Nutt J G
On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.
Annals of neurology 1987;22(4):535-40.
-
1987: Gancher S T; Nutt J G
Diurnal responsiveness to apomorphine.
Neurology 1987;37(7):1250-3.
-
1987: Nutt J G; Woodward W R; Gancher S T; Merrick D
3-O-methyldopa and the response to levodopa in Parkinson's disease.
Annals of neurology 1987;21(6):584-8.
-
1987: Gancher S T; Nutt J G; Woodward W R
Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.
Neurology 1987;37(6):940-4.
-
1987: Nutt J G
Parkinson's disease: evaluation and therapeutic strategy.
Hospital practice (Office ed.) 1987;22(4):107-14, 119, 122 passim.
-
1987: Koller W; O'Hara R; Weiner W; Lang A; Nutt J; Agid Y; Bonnet A M; Jankovic J
Relationship of aging to Parkinson's disease.
Advances in neurology 1987;45():317-21.
-
1986: Nutt J G; Woodward W R; Carter J H
Clinical and biochemical studies with controlled-release levodopa/carbidopa.
Neurology 1986;36(9):1206-11.
-
1986: Nutt J G; Woodward W R
Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients.
Neurology 1986;36(6):739-44.
-
1986: Koller W; O'Hara R; Nutt J; Young J; Rubino F
Monozygotic twins with Parkinson's disease.
Annals of neurology 1986;19(4):402-5.
-
1986: Bharucha N E; Stokes L; Schoenberg B S; Ward C; Ince S; Nutt J G; Eldridge R; Calne D B; Mantel N; Duvoisin R
A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors.
Neurology 1986;36(2):284-8.
-
1986: Gancher S T; Nutt J G
Autosomal dominant episodic ataxia: a heterogeneous syndrome.
Movement disorders : official journal of the Movement Disorder Society 1986;1(4):239-53.
-
1986: Hammerstad J P; Carter J; Nutt J G; Casten G C; Shrotriya R C; Alms D R; Temple D
Buspirone in Parkinson's disease.
Clinical neuropharmacology 1986;9(6):556-60.
-
1985: Nutt J G; Woodward W R; Anderson J L
The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
Annals of neurology 1985;18(5):537-43.
-
1985: Nutt J G; Hammerstad J P; Carter J H; deGarmo P L
Lisuride treatment of focal dystonias.
Neurology 1985;35(8):1242-3.
-
1984: Nutt J G; Carter J H
Sensory symptoms in parkinsonism related to central dopaminergic function.
Lancet 1984;2(8400):456-7.
-
1984: Nutt J G; Woodward W R; Hammerstad J P; Carter J H; Anderson J L
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
The New England journal of medicine 1984;310(8):483-8.
-
1984: Nutt J G; Bird T D
Essential myoclonus in a kindred with familial malignant melanoma.
Archives of neurology 1984;41(2):189-91.
-
1984: Nutt J G; Hammerstad J P; deGarmo P; Carter J
Cranial dystonia: double-blind crossover study of anticholinergics.
Neurology 1984;34(2):215-7.
-
1984: Ward C D; Duvoisin R C; Ince S E; Nutt J D; Eldridge R; Calne D B; Dambrosia J
Parkinson's disease in twins.
Advances in neurology 1984;40():341-4.
-
1984: Nutt J G; Fellman J H
Pharmacokinetics of levodopa.
Clinical neuropharmacology 1984;7(1):35-49.
-
1983: Shah A B; Coull B M; Howieson J; Ono H; Nutt J G; Blank N K; Carter J
Does the natural history of transient ischemic attacks (TIAs) justify surgery?
Stroke; a journal of cerebral circulation 1983;14(5):827-8.
-
1983: Ward C D; Duvoisin R C; Ince S E; Nutt J D; Eldridge R; Calne D B
Parkinson's disease in 65 pairs of twins and in a set of quadruplets.
Neurology 1983;33(7):815-24.
-
1983: Nutt J G
Effect of cholinergic agents in Huntington's disease: a reappraisal.
Neurology 1983;33(7):932-5.
-
1983: Golper L A; Nutt J G; Rau M T; Coleman R O
Focal cranial dystonia.
The Journal of speech and hearing disorders 1983;48(2):128-34.
-
1983: Nutt J G; Hammerstad J P; Carter J H; deGarmo P
Meige syndrome: treatment with trihexyphenidyl.
Advances in neurology 1983;37():201-5.
-
1983: Nutt J G; Morgan N T
Acute effects of scopolamine in Huntington's disease.
Advances in neurology 1983;37():291-7.
-
1981: Nutt J G; Hammerstad J P
Blepharospasm and oromandibular dystonia (Meige's syndrome) in sisters.
Annals of neurology 1981;9(2):189-91.
-
1981: Duvoisin R C; Eldridge R; Williams A; Nutt J; Calne D
Twin study of Parkinson disease.
Neurology 1981;31(1):77-80.
-
1981: Margolin D I; Nutt J G; Lovrien E W
Familial periodic ataxia.
Transactions of the American Neurological Association 1981;106():53-7.
-
1980: Nutt J G; Mrox E A; Leeman S E; Williams A C; Engel W K; Chase T N
Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction.
Neurology 1980;30(12):1280-5.
-
1980: Beasley B L; Nutt J G; Davenport R W; Chase T N
Treatment with tryptophan of levodopa-associated psychiatric disturbances.
Archives of neurology 1980;37(3):155-6.
-
1979: Nutt J G; Kupferberg H J
Linear relationship between plasma concentration and dosage of sodium valproate.
Epilepsia 1979;20(6):589-92.
-
1979: Nutt J; Williams A; Plotkin C; Eng N; Ziegler M; Calne D B
Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1979;6(3):337-43.
-
1979: Neophytides A N; Nutt J G; Lodish J R
Thrombocytopenia associated with sodium valproate treatment.
Annals of neurology 1979;5(4):389-90.
-
1978: Nutt J G; Rosin A J; Eisler T; Calne D B; Chase T N
Effect of an opiate antagonist on movement disorders.
Archives of neurology 1978;35(12):810-1.
-
1978: Calne D B; Williams A C; Nutt J G; Neophytides A; Eisler T; Teychenne P F
Ergot derivatives for Parkinsonism.
The Medical journal of Australia 1978;2(3 Suppl):25-6.
-
1978: Nutt J G; Rosin A; Chase T N
Treatment of Huntington disease with a cholinergic agonist.
Neurology 1978;28(10):1061-4.
-
1978: Nutt J G; Neophytides A N; Lodish J R
Lowered erythrocyte-sedimentation rate with sodium valproate.
Lancet 1978;2(8090):636.
-
1978: Calne D B; Plotkin C; Williams A C; Nutt J G; Neophytides A; Teychenne P F
Long-term treatment of parkinsonism with bromocriptine.
Lancet 1978;1(8067):735-8.
-
1977: Nutt J G
Lid abnormalities secondary to cerebral hemisphere lesions.
Annals of neurology 1977;1(2):149-51.
-
1977: Jasinski D R; Nutt J G; Haertzen C A; Griffith J D; Bunney W E
Lithium: effects on subjective functioning and morphine-induced euphoria.
Science (New York, N.Y.) 1977;195(4278):582-4.
-
1975: Griffith J D; Nutt J G; Jasinski D R
A comparison of fenfluramine and amphetamine in man.
Clinical pharmacology and therapeutics 1975;18(5 Pt 1):563-70.
-
1974: Jasinski D R; Nutt J G; Griffith J D
Effects of diethylpropion and d-amphetamine after subcutaneous and oral administration.
Clinical pharmacology and therapeutics 1974;16(4):645-52.
-
1974: Nutt J G; Jasinski D R
Methadone-naloxone mixtures for use in methadone maintenance programs. I. An evaluation in man of their pharmacological feasibility. II. Demonstration of acute physical dependence.
Clinical pharmacology and therapeutics 1974;15(2):156-66.
Sign-in to see more
